Abstract Morphine has been shown to increase the expression of brain-derived neurotrophic factor (BDNF) in the brain. However, little is known about the effect of morphine withdrawal on BDNF and its precursor protein, or proBDNF, which induces neuronal apoptosis. In this work, we examined whether BDNF and proBDNF levels change in rats chronically injected with escalating doses of morphine and those who undergo spontaneous withdrawal for 60 h. We observed, in the frontal cortex and striatum, that the ratio of BDNF to proBDNF changed depending upon the experimental paradigm. Morphine treatment and morphine withdrawal increased both BDNF and proBDNF levels. However, the increase in proBDNF immunoreactivity in withdrawal rats was more robust than that observed in morphine-treated rats. proBDNF is processed either intracellularly by furin or extracellularly by the tissue plasminogen activator (tPA)/plasminogen system or matrix metalloproteases (MMPs). To examine the mechanisms whereby chronic morphine treatment and morphine withdrawal differentially affects BDNF/proBDNF, the levels MMP-3 and MMP-7, furin, and tPA were analyzed.
Introduction
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that prevents the injury of different neuronal populations (Han and Holtzman 2000; Hyman et al. 1991; Mamounas et al. 1995) and plays a pivotal role in brain plasticity-related processes such as learning and memory (Park and Poo 2013) . BDNF may also have a role in the molecular and cellular modifications underlying opioid abuse because higher blood levels of BDNF are associated with increased craving for heroin (Heberlein et al. 2011) . In addition, a polymorphism (Val66Met) in the BDNF gene, which regulates the release of BDNF (Egan et al. 2003) , has been linked to heroinseeking behavior (Greenwald et al. 2013) . In animals, morphine administration increases BDNF expression in selected brain areas (Hatami et al. 2007; Koo et al. 2012; Mashayekhi et al. 2012; Numan et al. 1998; Vargas-Perez et al. 2009 ). These and other findings (Akbarian et al. 2002) 
have indicated
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Materials and Methods

Reagents
Morphine sulfate was received from the National Institutes of Drug Abuse (NIH, Division of Neuroscience & Behavioral Research, Research Triangle Park, NC) . Morphine was diluted in isotonic and filtered sterilized saline. All other chemicals were commercially obtained, reagent grade.
Animals
All studies were carried out following the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health and approved by Georgetown University Animal Care and Use Committee.
Three-month-old male Sprague-Dawley rats (Charles River, Germantown, MD) were acclimated for a minimum of 1 week prior to conducting experiments. Animals were housed under standard conditions, two per cage, with food and water available ad libitum, and were maintained on a 12-h light/dark cycle for the duration of the treatment protocols. Rats received either a single injection of morphine (10 mg/kg), subcutaneously (s.c.) or saline, or were treated with escalating doses of morphine from 10 to 30 mg/kg twice a day over the course of 5 days to cause dependence as previously described (Campbell et al. 2013) . To cause morphine withdrawal, animals were treated with increasing dosages of morphine for 5 days as described above, after which, morphine treatment was ceased. Withdrawal symptoms were observed for 60 h and included diarrhea, weight loss, piloerection, and irritability, compared to control animals (Campbell et al. 2013) . After the treatments, animals were anesthetized with a mixture of ketamine/xylazine (80 and 20 mg/kg, respectively) and intracardially perfused with icecold phosphate-buffered saline. Whole brains were quickly removed and frontal cortex and striatum were dissected on ice for biochemical analysis.
Cortical Neurons
Cortical neurons were prepared from the cortex of embryonic (E17-18) Sprague-Dawley rats (Charles River, MA) following an established protocol (Avdoshina et al. 2010) . Cells were seeded onto poly-L-lysine pre-coated plates in Neurobasal Medium containing 2% B27 supplement, 25 nM glutamate, 0.5 mM L-glutamine, and 1% antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA). Cultures were grown at 37°C in 5% CO 2 /95% air for 8 days on glass coverslips. The presence of neurons and non-neuronal cells was verified by staining coverslips with the following antibodies: class III β-tubulin (1:1000; Covance, Emeryville, CA), glial fibrillary acidic protein (1:250, Abcam, Cambridge, MA), and ionized calcium binding adaptor molecule 1 (1:500; Wako Chemicals USA, Inc., Richmond, VA) to visualize neurons, astrocytes, and microglia, respectively. At the time of the experiments, cultures contained~5% nonneuronal cells.
Western Blot Analysis
Brain areas were homogenized in RIPA buffer (EMD Millipore, Billerica, MA) containing protease-phosphatase inhibitors (Roche Applied Science, Indianapolis, IN) by sonication and protein elution at 4°C. For the detection of mBDNF and proBDNF, lysates were subjected to immunoprecipitation, as previously described (Bachis et al. 2012) . In brief, protein levels in the lysates were measured by the Bradford Coomassie blue colorimetric assay (Bio-Rad Laboratories Inc., Hercules, CA). Equal amount of proteins were precleared using precipHen (Aves Labs, Tigar, OR) or protein A-Sepharose beads (SigmaAldrich, St. Louis, MO), and the supernatant was then incubated for 18 h at 4°C with an anti-BDNF antibody (5 μg/ml, EMD Millipore), as previously described ).
Immunoprecipitates were collected by centrifugation for 5 min at 5000 rpm. Beads were washed in lysis buffer and immune complexes were resolved by SDS-PAGE. Proteins were transferred onto a PVDF membrane and blocked with 25 mM Tris and 1% Tween (TBS-T) containing 5% milk powder. Blots were then incubated overnight with the anti-BDNF antibody (1:1000, Promega Corp., Madison, WI).
For matrix metalloproteinases (MMPs), tissue lysates were loaded on a PVDF membrane and analyzed by an anti-MMP-3 (1:500, EMD Millipore) and anti-MMP-7 (1:200, Abcam) antibodies. Blots were washed with TBS-T and incubated with correspondent peroxidase-conjugated secondary antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature. To assure for equal protein loading, membranes were stripped with Restore Western Blot Stripping Buffer (Invitrogen) for 30 min at 37°C and reprobed with a mouse monoclonal β-actin (1:5000, Sigma-Aldrich) antibody.
Immunoreactivity was detected by enhanced chemiluminescence (Thermo Fisher Scientific, Waltham, MA). The intensity of immunoreactive bands was quantified using ImageJ (National Institute of Health, Bethesda, MD).
Enzyme-Linked Immunosorbent Assay
Protein levels in the lysates were measured by the Bradford Coomassie blue colorimetric assay (Bio-Rad). Fifty micrograms of proteins was then used to measure the levels of mBDNF and proBDNF by enzyme-linked immunosorbent assay (ELISA) immunoassay kits from Aviscera Bioscience (Yoshida et al. 2012) or Promega Corp., respectively, according to the manufacturer's instructions, as previously described (Bachis et al. 2012) . For the proBDNF ELISA, recombinant mBDNF did not demonstrate measurable immunoreactivity below 5 ng/ml as determined by running in parallel a standard curve with proBDNF. Above this concentration, recombinant mBDNF demonstrated an approximately 14% cross-reactivity with the ELISA kit (supplementary figure) .
For the measurement of mBDNF and proBDNF in neuronal culture media, medium from neurons was collected on ice, centrifuged at 10,000 rpm for 10 min, and concentrated using Amicon® ultracentrifugal filters (EMD Millipore), following the manufacturer's instructions.
Furin levels were determined using an ELISA from R&D System (Minneapolis, MN) as previously described (Bachis et al. 2012) . Total and functionally active tPA levels were determined using ELISA from Innovative Research Inc. (Novi, MI), according to the manufacturer's instructions.
Statistical Analysis
Statistical analysis was calculated by ANOVA and post hoc Tukey test for multiple comparisons using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). P values of <0.05 indicate statistical significance.
Results
Morphine and Morphine Withdrawal Change the Ratio mBDNF/proBDNF In Vivo
Morphine dependence and withdrawal differentially affect the expression of pro-inflammatory cytokines in the frontal cortex and striatum but not in the hippocampus or cerebellum (Campbell et al. 2013) . To examine whether the same treatments alter mBDNF and proBDNF levels, rats were injected subcutaneously for 5 days with saline or escalating doses of morphine that induce dependence, as described in the BMaterials and Methods^section. Rats were euthanized 2 h after the last injection. For comparison, rats also received an acute treatment of saline or an acute dose of morphine and were sacrificed 2 h after the injection. To determine the effect of withdrawal, rats received an escalating dose of morphine for 5 days and were allowed to undergo spontaneous withdrawal for 60 h prior to euthanasia.
The levels of mBDNF and proBDNF were then first determined in the frontal cortex by Western blot analysis. Tissue lysates were immunoprecipitated with a BDNF antibody that recognizes both mBDNF and proBDNF immunoreactivity and probed with a different BDNF antibody, as previously described (Bachis et al. 2012) . Two immunoreactive bands migrating at an apparent molecular weight of~14 and~34 kDa corresponding to mBDNF and proBDNF, respectively, were detected (Fig. 1a) . All morphine paradigms increased mBDNF, although the intensity of the 14 kDa band was stronger in the chronic morphine-treated and withdrawal rats than acute morphine group (Fig. 1a) . Likewise, the 34-kDa proBDNF band was increased in chronic morphine and withdrawal groups when compared to either saline or acute morphine (Fig. 1a) . Moreover, densitometric analysis of the 14-and 34-kDa bands revealed that morphine withdrawal significantly decreased the ratio mBDNF/ proBDNF when compared to chronic morphine treatment (Fig.  1b) .
To confirm the effect of morphine and morphine withdrawal, we analyzed mBDNF and proBDNF levels in the frontal cortex by ELISA. Both chronic morphine administration and withdrawal increased mBDNF compared to saline controls (Fig. 2a) . Furthermore, the increase in proBDNF by withdrawal was significantly higher than that obtained after chronic morphine administrations (Fig. 2a) , supporting the data obtained by Western blot analysis. Thus, we suggest that chronic morphine treatment and withdrawal differentially affect proBDNF levels.
BDNF is produced in neurons of the cerebral cortex and is delivered by anterograde transport to striatal neurons (Altar et al. 1997) . Therefore, we examined whether the effects of morphine and withdrawal seen in the frontal cortex could be reproducible in the striatum using the same animal groups. We observed that chronic morphine treatment increased the levels of mBDNF without a significant increase in proBDNF (Fig. 2b) . In animals undergoing withdrawal, there was a significant increase in proBDNF while mBDNF did not change compared to saline controls (Fig. 2b) . Thus, withdrawal decreases the ratio mBDNF/proBDNF in this brain area as well.
Chronic Morphine and Processing Enzymes
proBDNF is cleaved intracellularly by the enzyme furin and extracellularly by MMPs, in particular MMP-3 and MMP-7 and plasmin (Pang et al. 2004) . Morphine may change the activity of one or more of these processing enzymes. Indeed, morphine has been shown to increase the levels and activity of tPA (Nagai et al. 2004; Yamada et al. 2005 ), a serine protease that is released in an activity-dependent manner (Bruno and Cuello 2006) and plays a role in proBDNF processing by converting plasminogen into plasmin (Pang et al. 2004) . Therefore, in an attempt to reveal the molecular mechanisms through which chronic morphine treatment and withdrawal could be affecting the levels of proBDNF, we determined Fig. 2 Morphine withdrawal increases proBDNF. Male rats were treated s.c. with saline or escalating doses of morphine for 5 days. A group of animals was allowed to undergo spontaneous withdrawal for 60 h. The levels of mBDNF and proBDNF were then measured by ELISA in the frontal cortex (a) and striatum (b). Data, expressed as picogram per milligram of protein, are the mean ± SEM of five animals per group. **p < 0.01, ***p < 0.001 vs. saline; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. chronic morphine Fig. 1 Chronic morphine treatment and morphine withdrawal change the ratio proBDNF/mBDNF in the frontal cortex. Male rats were treated s.c. with saline or escalating doses of morphine for 5 days and were euthanized 2 h later. Another group of rats received an acute dose of morphine 2 h prior to euthanasia. A third group of animals received chronic morphine and was allowed to undergo spontaneous withdrawal for 60 h. The levels of mBDNF and proBDNF were then measured by Western blot in tissue lysates from the frontal cortex following immunoprecipitation. a Example of Western blot analysis. Lysates were immunoprecipitated with an antibody against BDNF. The blot was then analyzed with a BDNF antibody that recognizes both the mature (14 kDa) and pro form of BDNF (34 kDa). b Densitometric analysis of BDNF-like immunoreactivity expressed as the ratio mBDNF/proBDNF immunoreactivity. Data are the mean ± SEM of four rats per group. *p < 0.01 vs. saline, #p < 0.05 vs. chronic morphine the levels of these enzymes in the frontal cortex of chronic morphine and withdrawal animals.
Western blot analysis of MMP-3 and MMP-7 immunoreactivity revealed that neither chronic morphine nor withdrawal changed their levels when compared to saline (Fig. 3) . Similarly, using a sensitive ELISA (Bachis et al. 2012) , we found no changes in furin levels (Fig. 4a) in any treatment groups, overall suggesting that the levels of these enzymes are not affected by morphine or withdrawal. However, chronic morphine and withdrawal differentially affected tPA. In fact, while chronic morphine increased tPA levels, withdrawal decreased it when compare to saline control (Fig. 4b) .
Increased levels of tPA alone may not reveal whether this enzyme is actively promoting the processing of proBDNF. Therefore, we determined the levels of functionally active tPA by ELISA. We found that while chronic morphine treatment increased activated tPA levels when compared to saline controls, withdrawal decreased them (Fig. 4b) . Collectively, these data suggest that the different ratio mBDNF/proBDNF evoked by chronic morphine administration and morphine withdrawal is due to processing of proBDNF.
Chronic Morphine Affects the Release of proBDNF and mBDNF In Vitro
proBDNF is neurotoxic after it has been released into the synaptic cleft. However, measuring proBDNF release in vivo is challenging. Therefore, we used primary rat cortical cells in culture. Cortical neurons were exposed to 1 μM morphine every 24 h for 5 days. The amount of mBDNF and proBDNF released by the cells was determined in the concentrated medium by ELISA using an antibody specific for mBDNF or proBDNF, as previously described (Bachis et al. 2012) . The time course analysis shows that morphine elicits a temporal increase in mBDNF in the medium on days 4 and 5 (Fig. 5a) concomitantly to a reduction of proBDNF by day 3 of treatment ( Fig. 5a ).
To establish whether there is a correlation between morphine, tPA, and proBDNF, cortical neurons were exposed to morphine for different time points, alone or in combination with plasminogen activator inhibitor-1 (PAI-1), a tPA inhibitor (Cale and Lawrence 2007) . PAI-1 was added to neurons concomitantly with morphine, starting at day 3. Low concentrations of PAI-1 (100 ng/ml) were used due to its toxicity (Flavin et al. 2000) . We observed that PAI-1 abrogated both Fig. 3 Morphine does not change the levels of MMPs. Cortical lysates were obtained from animals treated with saline, chronic morphine, or undergoing withdrawal. a Example of a Western blot of lysates from t w o r a t s e a c h g r o u p a n a l y z e d f o r M M P -3 a n d M M P -7 immunoreactivity. MMP-3 and MMP-7 bands migrate with an apparent molecular weight of 53 and 22 kDa, respectively. The blot was washed and reprobed with a β-actin antibody for loading control. b Relative levels of MMPs were calculated by optical density and normalized by ß-actin immunoreactivity. Data, expressed as arbitrary units, are the mean ± SEM of four separate samples each group Fig. 4 Morphine and morphine withdrawal differentially change the levels of tPA. Male rats were treated s.c. with saline or escalating doses of morphine. A group of animals was allowed to undergo spontaneous withdrawal for 60 h. Levels of furin (a), total tPA, and activated tPA (b) were then measured in the frontal cortex by ELISA. Data, expressed as percent of saline control, are the mean ± SEM of five animals per group. *p < 0.01 vs. saline control, #p < 0.05 vs. saline control the morphine-mediated decrease of proBDNF release and increase in mBDNF release (Fig. 5b) , further suggesting a central role of tPA in regulating morphine-induced changes in the mBDNF/proBDNF ratio.
Discussion
We have previously shown that morphine withdrawal promotes neuronal apoptosis by increasing pro-inflammatory cytokines and microglia (Campbell et al. 2015) . The present work aims to provide more insights into the neurotoxic mechanisms of morphine withdrawal, by looking at its effect on proBDNF. proBDNF is a secreted protein that binds to p75NTR and induces neurotoxic events such as apoptosis , growth cone collapse , presynaptic terminal retraction (Je et al. 2013) , and axonal degeneration (Bachis et al. 2012) . Our study shows that mBDNF is increased by both chronic morphine treatment and withdrawal but withdrawal augments proBDNF so that it significantly decreases the ratio mBDNF/proBDNF. Moreover, we have shown that morphine dependence and morphine withdrawal differentially alter the levels of tPA, a protease that is implicated in proBDNF cleavage. Overall, our findings suggest that chronic morphine and morphine withdrawal alters the ratio mBDNF/ proBDNF by modifying proBDNF processing.
proBDNF is packaged in dense core vesicles (Dieni et al. 2012) , transported as a complex with Huntingtin associated protein-1 and sortilin Yang et al. 2011) , and released into the synaptic cleft where it can be cleaved by MMPs and the serine protease plasmin (Pang et al. 2004) . Plasmin, which is initially produced as inactive plasminogen, requires cleavage by tPA (Plow et al. 1995) which is released upon neuronal activation (Bruno and Cuello 2006) . Decreased tPA release has been shown to correlate with the ability of proBDNF to induce neuronal apoptosis (Head et al. 2009 ), supporting the notion that neuronal activity coordinates the simultaneous release of proneurotrophins and processing enzymes (Bruno and Cuello 2006) . Our findings show that neither furin nor MMP levels are changed by chronic morphine or withdrawal but tPA is activated by morphine and reduced by withdrawal. In addition, the tPA inhibitor PAI-1 reversed the effect of chronic morphine on mBDNF/proBDNF in cortical neurons, suggesting that the tPA/plasminogen system most likely mediates morphine-induced processing of proBDNF to mBDNF. Our data support previous studies showing that repeated doses of morphine increase tPA expression (Berta et al. 2013) . Our data join a growing number of studies that have shown the importance of tPA in proBDNF processing and neuronal plasticity. Indeed, tPA knockout mice, which exhibit increased levels of proBDNF in the hippocampus (Pang et al. 2004) , have impaired synaptic plasticity (Matys et al. 2004; Pawlak et al. 2003) and reduced longterm potentiation (Calabresi et al. 2000) . Importantly, this scenario is similar to that described in the brain of rodents undergoing morphine withdrawal. In fact, opiate withdrawal has been shown to decrease the number and complexity of dendritic spines in brain reward circuitry neurons (Robinson et al. 2002) including the ventral tegmental area (Russo et al. 2009; Spiga et al. 2003) . Although more studies are needed to examine in more detail the neuroanatomical induction of proBDNF during withdrawal, our data suggest that proBDNF might be responsible for some of the morphological changes induced by morphine withdrawal.
The data presented here indicate that morphine withdrawal increases proBDNF by reducing its extracellular processing. Unprocessed extracellular proBDNF can lead to activation of p75NTR, which results in damage to neuronal processes and remodeling , as well as reduced long-term potentiation. Moreover, when proBDNF is not cleaved, the Rat cortical neurons were exposed to 1 μΜ morphine or saline control each day for 5 days. a Medium was collected at the indicated time points, and levels of BDNF and proBDNF were measured by ELISA in the concentrated media. Data are expressed as percent of control because the basal levels of neurotrophins fluctuated throughout the experiments. b Cortical neurons were exposed to morphine or saline control for 3 days. Starting at day 3, PAI-1 (100 ng/ml) was added concomitantly with morphine. Data, expressed as percent of control, are the mean ± SEM of three separate experiments in duplicate. *p < 0.01, #p < 0.05 vs. control availability of mBDNF is drastically reduced. Lack of or reduced mBDNF has been suggested to be one of the causes of the neuropathology observed in various neurodegenerative diseases, including Parkinson's (Howells et al. 2000; Toda et al. 2003 ) and Huntington's disease (Ciammola et al. 2007) , and human immunodeficiency virus (HIV)-associated dementia (HAND) (Bachis et al. 2012) . While transcriptional mechanisms mediate the decrease in mBDNF in Parkinson's and Huntington's disease (Zuccato and Cattaneo 2009) , in HAND, it appears that impaired processing of proBDNF is the main cause of low levels of mBDNF. In fact, the basal ganglia of HAND exhibit reduced furin and tPA levels, concomitantly to higher levels of proBDNF, than HIV subjects without dementia (Bachis et al. 2012 ). This scenario is similar to that characterized here, supporting a suggestion that opioid withdrawal, not abuse, may accelerate the progression of neurological impairment such as that seen in HAND subjects (Bandaru et al. 2011) .
In this study, we present evidence that morphine withdrawal increases the pro-apoptotic proBDNF. However, proBDNF is not the only neurotrophin that is neurotoxic by binding to p75NTR. In fact, pro-nerve growth factor binds to p75NTR and promotes neurotoxicity of various cell types (Beattie et al. 2002; Lebrun-Julien et al. 2010; Nykjaer et al. 2004 ). Moreover, the intracellular or extracellular processing of proBDNF, in addition to mBDNF, generates a BDNF prodomain, the amino-terminal portion of proBDNF (Anastasia et al. 2013) . The prodomain interacts with sortilin and promotes growth cone retraction, similar to proBDNF (Anastasia et al. 2013) . In our study, we did not examine whether withdrawal affects these two ligands, which are also released from neurons (Anastasia et al. 2013; Harrington et al. 2004) ; moreover, the antibody against proBDNF could detect the BDNF prodomain as well. Therefore, we cannot rule out that other pro-apoptotic neurotrophins could be released during morphine withdrawal and be involved in its neurotoxic effects. In addition, withdrawal from morphine can positively affect the production of pro-inflammatory cytokines such as interleukin-1β and tumor necrosis factor-α and negatively affect the production of anti-inflammatory cytokines such as CCL5 (Campbell et al. 2013; Desjardins et al. 2008; Eisenstein et al. 2006; Hutchinson et al. 2011) . Likewise, withdrawal can increase susceptibility to outside pathogens (Eisenstein et al. 2006) . For example, opioid withdrawal can reduce the levels of circulating lymphocytes in morphine-dependent macaques (Weed and Steward 2005) or exacerbate the neurotoxic effect of the HIV protein gp120 (Campbell et al. 2015) . Moreover, an in vitro study of HIV-infected lymphocytes has revealed enhanced HIV replication in both abrupt (cessation of treatment) and precipitated (by naloxone) opioid withdrawal (Desjardins et al. 2008) . Thus, one could suggest that opioid withdrawal in viral infectious diseases may increase neuronal susceptibility to the toxic effects of the virus.
Drug abuse is a complex disease. In humans, it often involves cycles of intoxication followed by withdrawal either during recovery from opioid abuse or during intermittent periods where addicts Bseek out^more abusive substances. In the future, it will be important to establish whether drug abusers with a single nucleotide polymorphism in the BDNF gene, such as Val66Met, which impairs the release of mBDNF (Egan et al. 2003) , are more at risk than non-polymorphic subjects to develop neurological alterations.
